FTSE MIB
28.135,83 -107,43 (-0,38%) Dow Jones
33.507,50 -158,80 (-0,47%) Nasdaq
13.219,32 +18,02 (+0,14%) Nikkei 225
31.759,88 -97,72 (-0,31%) Petrolio
91,14 +0,35 (+0,39%) Bitcoin EUR
26.823,31 +1.046,73 (+4,06%)
Medigene AG (0QGJ.L)
| Chiusura precedente | 1,7000 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 90 |
| Capitalizzazione | 427.293 |
| Beta (5 anni mensile) | 0,94 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4060 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireMedigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed
- GlobeNewswire
Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library
Planegg/Martinsried, September 18, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that it has selected its lead candidate for MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costim
- GlobeNewswire
Medigene AG to present at the Baader Investment Conference 2023
Planegg/Martinsried, September 11, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023. Corporate presentation - Baader Investment Conference 2023 https://www.baaderinvestmentconference.com/Date and time: Monday, September 18, 2023, 2:10 pm – 2:50
